Comparison Study of Oxytocin Versus Tranexamic Acid and Etamsylaye Versus Placebo(Saline)

Comparison Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate Versus Placebo to Reduce Blood Loss Intraoperative and Post Operative During Elective Cesarean Section

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05273632

Enrollment

300

Registered

2022-03-10

Start date

2022-03-20

Completion date

2022-09-30

Last updated

2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Loss, Postoperative, Blood Loss, Surgical

Keywords

blood loss, cesarean section, oxytocin, tranexamic acid, etamsylate, saline, Intra-operative, Postoperative

Brief summary

Comparison Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate Versus Normal Saline as Pre-operative Administration.

Detailed description

Comparison Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate Versus Normal Saline to reduce intra operative bleeding and postoperative bleeding during elective Cesarean Delivery.

Interventions

DRUGOxytocin

trial of reduction of losing blood intra operative or post operative during Cesarean Delivery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Pregnant females admitted for Elective Cesarean Section. * Gestational age of pregnancy (38 weeks To 40 weeks). * the average height of 145 to 160 cm,average body weight of 45 to 85 kgs. * Singleton living fetus. * No medical disorders. * Informed Oral Consent From The Patient.

Exclusion criteria

* Severe medical and surgical disorders as thyroid dysfunction, which was excluded by routine thyroid function test (free T3, free T4, and thyroid stimulating hormone(TSH), all of them should be within normal limits). * Bleeding tendency, for example, disseminated intravascular coagulopathy, which was excluded by platelet count, coagulation time, bleeding time, prothrombin time, partial thromboplastin time, and thrombin time (all should be within normal). * Acute liver or kidney diseases; blood disorders, such as anaemia. * Allergy to Tranexamic acid. * Risk factors for PPH, such as polyhydramnios, fetal macrosomia, antepartum haemorrhage. * Ante partum Hemorrhage such placental abruption.

Design outcomes

Primary

Measure	Time frame	Description
blood loss during and after cesarean delivery	First 2 hours after C-Section	Measuring of Hemoglobin level and Hematocrit level pre and post operatively.

Secondary

Measure	Time frame	Description
post operative bleeding	first 24 hours after C-Section	assessment of Hemoglobin level and Hematocrit level post operatively.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026